Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.   (currently amended) A diagnostic kit for detection of a human cancer cell that expresses glypican-1, comprising: a binding molecule selected from the group consisting of an antibody and an antibody fragment that binds to human glypican-1, and optionally a reporting molecule attached to the binding molecule such that a detection method allows detection of the cancer by detection of the presence of the binding molecule via detection of the reporting molecule; and an <u>instruction</u> ~~information associated with the binding molecule~~ <u>that provides information</u> that binding of the binding molecule to a cell is indicative of a human cancer cell that <u>over</u>expresses glypican-1.

2.   (Original) The diagnostic agent of Claim 1, wherein the binding molecule comprises an antibody.

3.   (previously presented) The diagnostic agent of Claim 2, wherein the antibody is used to detect glypican-1 in a body fluid.

4.   (previously presented) The diagnostic agent of Claim 2, wherein the antibody is used to image glypican-1.

5.   (previously presented) A therapeutic kit comprising a therapeutic agent at a concentration effective to slow growth of human cancer cells identified to express glypican-1, wherein the agent comprises a molecule selected from the group consisting of an antibody and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1, cleaving an extracellular region of human glypican-1, and suppressing expression of an extracellular region of human glypican-1, and an <u>instruction</u> ~~information associated with the molecule~~ that <u>provides information that</u> binding of the binding molecule to the cancer cells slows growth of the cancer cells <u>that overexpress glypican-1.</u>

6.   (Previously presented) The composition of Claim 5, wherein the molecule comprises an antibody that binds to the extracellular region of glypican-1.

7.   (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.

8.   (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.

9.   (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.

10.   (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.

11.   (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.

12.   (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.

13.   (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.

14.   (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.

15.   (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.

16.   (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.

17.   (previously presented) The diagnostic kit of claim 1 wherein the human cancer cell is a pancreatic cancer cell or a breast cancer cell.

18.   (previously presented) The therapeutic kit of claim 5 wherein the human cancer cells are

pancreatic cancer cells or breast cancer cells.